Stoke Therapeutics (STOK) Interest & Investment Income (2019 - 2026)
Stoke Therapeutics (STOK) posted quarterly Interest & Investment Income of -$658000.0 for Q1 2026, down 122.77% year-over-year from $2.9 million in Q1 2025, and down 778.35% quarter-over-quarter from $97000.0 in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) Interest & Investment Income (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Interest & Investment Income history runs 8 years deep, the most recent figure standing at -$658000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 122.77% year-over-year to -$658000.0; the TTM figure through Mar 2026 stood at -$11000.0 (down 100.4% YoY), while the FY2025 annual figure was $694000.0, up 646.46% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$658000.0, down from $97000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $2.9 million in Q1 2025, with the low at -$658000.0 in Q1 2026.
- The 5-year median for Interest & Investment Income is $123000.0 (2023), against an average of $170352.9.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income slumped 2966.67% in 2022, then jumped 11941.67% in 2025.
- Stoke Therapeutics' Interest & Investment Income stood at $528000.0 in 2022, then tumbled by 76.7% to $123000.0 in 2023, then plunged by 357.72% to -$317000.0 in 2024, then soared by 130.6% to $97000.0 in 2025, then sank by 778.35% to -$658000.0 in 2026.
- Business Quant data shows STOK's Interest & Investment Income at -$658000.0 in Q1 2026, $97000.0 in Q4 2025, and $350000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 3.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.52 Mn |
| Mar 31, 2026 | -658,000.00 |
| Dec 31, 2025 | 3.62 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 3.79 Mn |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 24,000.00 |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 219,000.00 |
| Mar 31, 2023 | 577,000.00 |
| Dec 31, 2022 | 1.48 Mn |
| Sep 30, 2022 | 995,000.00 |
| Jun 30, 2022 | -592,000.00 |
| Mar 31, 2022 | -516,000.00 |
| Dec 31, 2021 | -252,000.00 |
| Sep 30, 2021 | 44,000.00 |